Device Trial Radar · NCT07578441
VitaSmart HOPE System: Bridge to HOPE Registry
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
5,000
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Dec 2028
Study completion Dec 2033
Sponsor
- Lead sponsor
- Bridge to Life Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- The Cleveland Clinic
- First posted
- May 11, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a post-market, multicenter, single-arm, observational registry evaluating real-world use of the VitaSmart HOPE System under standard of care conditions. Clinical data from up to 5000 transplant recipients will be included in the registry at up to 20 U.S. transplant centers. This registry will include clinical data collected retrospectively from medical records of recipients already transplanted before the initiation of the registry and any new recipients of livers that meet donor selection criteria. This registry introduces no contact with the transplant recipient and registry participants will follow standard of care. Data will be collected through up to 5 years of standard of care clinical follow-up. This registry represents minimal risk to the transplant recipients being studied. The participants included in this registry will have undergone transplant surgery with a deceased donor liver graft that was perfused using the VitaSmart HOPE System, a medical device that is cleared by the Food and Drug Administration (FDA) for commercial use in the U.S. All perfusions of deceased donor liver grafts will be performed in accordance with standard medical practice. The objectives of this registry is to Evaluate the safety and efficacy of HOPE prior to liver transplantation in real-world clinical settings.
Conditions
- End Stage Liver DIsease
- Liver Failure
Interventions
hypothermic oxygenated perfusion therapy of a donor liver under standard of care conditionsDevice
Observational, real-world use of the VitaSmart HOPE System with a donor liver graft under standard of care conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Recipients alive with functioning graft at 1-year post-transplantTime frame: 1-year post-transplant
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Georgetown University
Washington D.C., District of Columbia
Cleveland Clinic
Weston, Florida
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.